Advances in Radiation Immuno-Oncology: Progress at the Interface of Radiation Oncology and Immunotherapy—A Themed Issue in Honor of Prof. Dr. Gabriele Multhoff
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 9078
Special Issue Editors
2. CEO of Multimmune GmbH, Munich, Germany
Interests: cancer immunotherapy; heat shock proteins; immunoregulation; cancer therapeutics; cancer diagnostics; tumor immunity
Interests: immune modulation by radiation; tumor immunology; hyperthermia; vaccination; osteoimmunological mechanisms of low-dose radiation therapy; translational immune monitoring; combined radio-immunotherapies; prognostic and predictive immune biomarkers
Special Issues, Collections and Topics in MDPI journals
Interests: translational research; biomarker development; cancer radioimmunotherapy; low-dose anti-inflammatory radiation therapy; tumor microenviroment; survivin; molecular targeting
Special Issue Information
Dear Colleagues,
Prof. Dr. Gabriele Multhoff is Professor of Experimental Radiation Oncology and Radiation Biology and Head of the Radiation Immuno-Oncology Group at the Center for Translational Cancer Research (TranslaTUM) and the Department of Radiation Oncology at the Technical University of Munich (TUM), Klinikum rechts der Isar in Munich, Germany.
After studying biology at the Ludwig Maximilians Universität (LMU) Munich, Prof. Multhoff obtained her doctorate in immunology in 1990 and habilitated within the framework of a Möllemann habilitation scholarship in 1998. In 2002, she was appointed Professor of Experimental Hematology at the University Hospital Regensburg, from where she moved to her current position in 2007. Prof. Multhoff is also the founder, former CEO and current CSO of multimmune GmbH. In 2015, Prof. Dr. Gabriele Multhoff was awarded the 2015 CESAR (Central European Society of Anticancer Drug Research) Prize for outstanding work in the field of translational research on the development of anti-tumor agents, specifically her work on innovative cellular, molecular and antibody-mediated immunotherapies.
Prof. Gabriele Multhoff’s research focusses on the development of innovative cell-, molecule- and antibody-based targeted immunotherapies that are primarily based on her seminal discovery that tumors selectively express a membrane form of heat shock protein 70 (Hsp70), and she is combining these new therapeutic approaches with conventional radiation therapy and chemotherapy. Her work has led to the successful delivery of a randomized, multicenter phase II clinical study entitled “Targeted NK cell-based adjuvant immunotherapy for the treatment of patients with non-small cell lung carcinoma (NSCLC) after radiochemotherapy”. Her group has established a novel screening test to quantify liposomal, tumor-derived Hsp70 and a method to isolate circulating tumor cells (CTCs) from patients with a variety of cancers.
Prof. Multhoff’s research interests also include the application of novel in vivo imaging techniques such as intraoperative, fluorescence molecular tomography (FMT), multispectral optoacoustic tomography (MSOT) and PET/CT after CT-guided irradiation of tumors and the analysis of cellular, molecular biological and immunological mechanisms in tumors and normal cells, including primary endothelial cells, after exposure to radiation, as well as the development of innovative nanoparticle-based theranostica.
Based on her sustained, impressive contributions to the field and their translational relevance, we are delighted to act as Guest Editors for this Special Issue of Cancers honoring her significant achievements. The prime focus of this Special Issue is to highlight her outstanding achievements in translational radiation immuno-oncology and her critical role in advancing the field. We are very pleased to invite Gabriele Multhoff’s collaborators and peers to submit a publication to this Special Issue, which we believe will stimulate thought and make a unique contribution to the field.
Prof. Dr. A. Graham Pockley
Prof. Dr. Udo S. Gaipl
Prof. Dr. Franz Rödel
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiation oncology
- radiotherapy
- tumor immunity
- immuno-oncology
- cancer immunotherapy
- cancer therapeutics
- cancer diagnostics
- cancer theranostics
- imaging
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Reprogramming the immunosuppressive tumor microenvironment to improve responses to radiation therapy and immunotherapy combinations
Authors: Tim Illidge
Affiliation: Faculty of Biology, Medicine and Health, The University of Manchester, The Christie NHS Foundation Trust
Abstract: Radiotherapy (RT) is an important part of cancer treatment delivered to around 50% of all cancer patients. In addition to its direct tumoricidal effects RT can induce profound immunomodulatory effects in the surrounding tumor microenvironment (TME) which can be both immunostimulatory and immunosuppressive. Immune checkpoint inhibitors (ICIs) directed against the programmed death ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte associated antigen 4 (CTLA-4) have revolutionized cancer therapy but are only effective in a minority of patients. Hundreds of clinical trials have been set-up investigating whether response rates and clinical outcomes could be improved with the combination of RT and ICIs. Reported results thus far have been disappointing and further investigation is required to understand the underlying mechanisms of therapeutic resistance to ICI and RT induced immunosuppression.
In this review the focus will be on mechanisms of RT induced immunosuppression including within the TME, including myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs) and macrophage populations and evolving therapeutic strategies to reprogramming the immunosuppressive TME. Emerging new approaches to overcome therapeutic resistance and improve responses to increase the generation of local and systemic anti-cancer immune response following RT and immunomodulatory agents, are discussed.